Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1034-1035 (29 April), doi:10.1136/bmj.332.7548.1034-b
| The first 150 words of the full text of this article appear below. |
EDITORWhiting et al ignore data collected over the past 15 years that show repeatedly that early diagnosis of multiple sclerosis is crucial and that early treatment leads to a far better outcome on numerous measures, immunological and clinical, than late treatment.1
In patients with one attack of multiple sclerosis starting immune therapy with interferon beta-1a can delay the patient meeting diagnostic criteria for clinically definite multiple sclerosis compared with untreated patients, and the untreated patients never quite catch-up when they eventually begin immune therapy.2 At this month's 58th annual meeting of the American Academy of Neurology San Diego another study (BENEFIT) using interferon beta-1b confirms the same point (M S Fredman; C H Polman, scientific sessions).
The management of multiple sclerosis has slowly been moving towards early diagnosis and treatment because it is the best way yet known to avoid the accumulation of significant deficits in the daily
Bharani Padmanabhan, director
Angels MS Service, Angels Neurological Centers, 536 Washington Street, Abington, MA 02351, USA scleroplex@earthlink.net